MTOR and pancreatic neoplasm: Moreover, a combination treatment with mTOR or PI3K/mTOR inhibitors together with other antitumor drugs appears to be a reasonable approach, because mTOR signaling is involved in a compensatory pathway that renders cancer cells drug resistant; thus, increased mTORC1 activity in breast and pancreatic cancer cells confers resistance to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors [100,101].